We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Monday
May 18
15:15 - 16:15
A6
Determinants of radiotherapy response
Ludwig Dubois, United Kingdom;
Turid Hellevik, Norway
Mini-Orals
Radiobiology
15:15 - 16:15
SCFA-producing gut microbiota associates with favourable chemoradiotherapy response, and SCFAs reduce Tregs and enhance tumour control in vivo
Chee Kin Then, Taiwan, Province of China
-570
15:15 - 16:15
High-LET dose linked to vasculopathy in children with craniopharyngioma treated by proton beam radiotherapy
Vadim Moskvin, USA
-296
15:15 - 16:15
Aldehyde dehydrogenase-mediated mechanisms of prostate cancer therapy resistance and bone metastasis formation
Ielizaveta Gorodetska, Germany
-2270
15:15 - 16:15
Enrichment of fibroblast activation protein+ cancer-associated fibroblasts contributes to radiotherapy resistance in muscle-invasive bladder cancer
Amy Burley, United Kingdom
-1161
15:15 - 16:15
Dual immune checkpoint inhibition sensitizes low-immunogenic orthotopic rectal cancer subtypes to radioimmunotherapy
Nicole Alisa Schmid, Germany
-2191
15:15 - 16:15
STING Activation Sustains CD8? T-Cell Function via Fatty-Acid Oxidation Following Fractionated Radiotherapy
Liqun Wang, China
-2011
15:15 - 16:15
CRISPR-based screening identifies novel radiation resistance targets in KRAS mutant lung cancer
Saif Ahmad, United Kingdom
-3462
15:15 - 16:15
AARS1 promotes Nasopharyngeal cancer proliferation and radiotherapy resistance through lactylation
Weisi Wang, China
-2007